T. Rowe Price Associates
RAPT

T. Rowe Price Associates’s RAPT Therapeutics RAPT Stock Holding History

T. Rowe Price Associates’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,972
Closed -$355K – 3048
2024
Q3 		$355K Sell
21,972
-4,090
-16% -$82.7K ﹤0.01% 2404
2024
Q2 		$637K Sell
26,062
-227,459
-90% -$10.5M ﹤0.01% 2092
2024
Q1 		$18.2M Sell
253,521
-173,173
-41% -$24.1M ﹤0.01% 994
2023
Q4 		$84.8M Sell
426,694
-15,786
-4% -$1.95M 0.01% 580
2023
Q3 		$58.8M Buy
442,480
+6,511
+1% +$1.06M 0.01% 638
2023
Q2 		$65.2M Buy
435,969
+21,485
+5% +$3.35M 0.01% 626
2023
Q1 		$60.8M Sell
414,484
-6,127
-1% -$1.24M 0.01% 629
2022
Q4 		$66.6M Buy
420,611
+35,643
+9% +$5.7M 0.01% 587
2022
Q3 		$74.1M Sell
384,968
-156,867
-29% -$29.7M 0.01% 547
2022
Q2 		$79.1M Buy
541,835
+44,997
+9% +$6M 0.01% 730
2022
Q1 		$87.4M Buy
496,838
+3,377
+0.7% +$638K 0.01% 775
2021
Q4 		$145M Buy
493,461
+5,689
+1% +$1.52M 0.01% 650
2021
Q3 		$121M Buy
487,772
+38,597
+9% +$10.2M 0.01% 702
2021
Q2 		$114M Buy
449,175
+126,694
+39% +$23.7M 0.01% 737
2021
Q1 		$57.3M Sell
322,481
-705
-0.2% -$116K 0.01% 962
2020
Q4 		$51.1M Sell
323,186
-5,317
-2% -$1.16M 0.01% 957
2020
Q3 		$84.6M Buy
328,503
+149,639
+84% +$33.2M 0.01% 710
2020
Q2 		$41.5M Buy
178,864
+16,228
+10% +$2.51M 0.01% 910
2020
Q1 		$27.1M Buy
162,636
+14,732
+10% +$3.36M ﹤0.01% 971
2019
Q4 		$31.9M Buy
+147,904
New +$27.2M ﹤0.01% 1047

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates's RAPT Position: Q4 2024 in Review

T. Rowe Price Associates sold out of RAPT Therapeutics (RAPT) in Q4 2024, closing a stake of 21,972 shares — an estimated $355K sold.

T. Rowe Price Associates first reported a position in RAPT in Q4 2019 and held it in 20 quarters. The position peaked at $145M in Q4 2021. 91 funds tracked by Wall St. Rank hold RAPT as of Q4 2024.

  • T. Rowe Price Associates reported no remaining RAPT Therapeutics position as of Q4 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 21,972 RAPT Therapeutics shares in Q4 2024, an estimated $355K.
  • T. Rowe Price Associates first reported a position in RAPT Therapeutics in Q4 2019 and held it in 20 quarters.
  • T. Rowe Price Associates's RAPT Therapeutics position peaked at $145M in Q4 2021.
  • 91 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.